Affiliation:
1. previously Cortexyme, Inc.
2. Department of Anatomy and Medical Imaging, The University of Auckland
3. Department of Pharmacology and Clinical Pharmacology, The University of Auckland
4. Lighthouse Pharmaceuticals; previously Cortexyme, Inc.
Abstract
Abstract
Gingipains are protease virulence factors produced by Porphyromonas gingivalis, a Gram-negative bacterium best known for its role in chronic periodontitis. Gingipains were recently identified in the middle temporal gyrus of postmortem Alzheimer’s disease (AD) brains, where gingipain load correlated with AD diagnosis and tau and ubiquitin pathology. Since AD and Parkinson’s disease (PD) share some overlapping pathologic features, including nigral pathology and Lewy bodies, the current study explored whether gingipains are present in the substantia nigra pars compacta of PD brains. In immunohistochemical techniques and multi-channel fluorescence studies, gingipain antigens were abundant in dopaminergic neurons in the substantia nigra of both PD and neurologically normal control brains. 3-dimensional reconstructions of Lewy body containing neurons revealed that gingipains associated with the periphery of alpha-synuclein aggregates but were occasionally observed inside aggregates. In vitro proteomic analysis demonstrated that recombinant alpha-synuclein is cleaved by lysine-gingipain, generating multiple alpha-synuclein fragments including the non-amyloid component fragments. Immunogold electron microscopy with co-labeling of gingipains and alpha-synuclein confirmed the occasional colocalization of gingipains with phosphorylated (pSER129) alpha-synuclein. In dopaminergic neurons, gingipains localized to the perinuclear cytoplasm, neuromelanin, mitochondria, and nucleus. These data suggest that gingipains may accumulate in dopaminergic neurons in the substantia nigra and interact with alpha-synuclein.
Publisher
Research Square Platform LLC
Reference60 articles.
1. Alpha synuclein, the culprit in Parkinson disease, is required for normal immune function;Alam MM;Cell Rep,2022
2. Parkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and Diagnosis;DeMaagd G;P T,2015
3. Motor imagery evokes increased somatosensory activity in Parkinson's disease patients with tremor;Helmich RC;Hum Brain Mapp,2012
4. Magrinelli, F. et al. Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinsons Dis 2016, 9832839 (2016). https://doi.org:10.1155/2016/9832839
5. Alpha-synuclein in Lewy bodies;Spillantini MG;Nature,1997